SCHEMBL2673237

SCHEMBL2673237

Oc1cccc(NC2CCN(CCc3ccccc3)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA4 P22748 2/20 0.57
CA5A P35218 2/20 0.57
CA7 P43166 2/20 0.57
CA9 Q16790 2/20 0.57
CA13 Q8N1Q1 2/20 0.57
CA14 Q9ULX7 2/20 0.57
SIGMAR1 Q99720 2/20 0.54
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CARM1 Q86X55 1/20 0.51
PRMT6 Q96LA8 1/20 0.51
OPRM1 P35372 1/20 0.51
OPRD1 P41143 1/20 0.51
OPRK1 P41145 1/20 0.51
ACHE P22303 1/20 0.50
CXCR3 P49682 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL916913 0.86 CA12 (0.71) CA12CA1CA2CA4CA5A
SCHEMBL2672877 0.85 CA12 (0.60) CA12CA1CA2CA4CA5A
SCHEMBL1823387 0.85 CA12 (0.57) CA12CA1CA2CA4CA5A
SCHEMBL1802253 0.85 CA12 (0.57) CA12CA1CA2CA4CA5A
SCHEMBL1818246 0.85 KDM4E (0.66) CA12CA1CA2CA4CA5A
SCHEMBL23805149 0.84 CXCR3 (0.58) CA12CA1CA2CA4CA5A
SCHEMBL5284466 0.81 HTR7 (0.54) CARM1PRMT6
SCHEMBL15934215 0.80 KDM4E (0.70) CARM1PRMT6DRD4
SCHEMBL18609760 0.80 CA12 (0.57) CA12CA1CA2CA4CA5A
SCHEMBL23649978 0.80 CA12 (0.60) CA12CA1CA2CA4CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200078353-A1 OLIGOMER-OPIOID AGONIST CONJUGATES INHERIS BIOPHARMA INC (US) 2020-03-12 US disclosed
CN-105503889-B Oligomer-opioid agonist conjugates 尼克塔治疗公司 2019-12-24 CN disclosed
US-20190247388-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2019-08-15 US disclosed
US-20190247388-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2019-08-15 US disclosed
US-10307416-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2019-06-04 US disclosed
US-10307416-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2019-06-04 US disclosed
US-20190046523-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2019-02-14 US disclosed
US-20190046523-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS 2019-02-14 US disclosed
US-10143690-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2018-12-04 US disclosed
US-20180296550-A1 Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound NEKTAR THERAPEUTICS 2018-10-18 US disclosed
US-20120184581-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2012-07-19 US disclosed
US-20120184581-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2012-07-19 US disclosed
US-20120184581-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2012-07-19 US disclosed
US-8173666-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2012-05-08 US disclosed
US-8173666-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2012-05-08 US disclosed
US-8173666-B2 Oligomer-opioid agonist conjugates NEKTAR THERAPEUTICS (US) 2012-05-08 US disclosed
WO-2011011543-A1 OLIGOMER-OPIOID AGONIST CONJUGATES NEKTAR THERAPEUTICS (US) 2011-01-27 WO disclosed
US-20100048602-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2010-02-25 US disclosed
US-20100048602-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2010-02-25 US disclosed
US-20100048602-A1 Oligomer-Opioid Agonist Conjugates NEKTAR THERAPEUTICS (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10143690-B2 Oligomer-opioid agonist conjugates OPRM1, OPRL1, OPRK1 CA12 3553/4885CA1 3927/4885CA2 4481/4885
US-20200078353-A1 OLIGOMER-OPIOID AGONIST CONJUGATES OPRM1, OPRL1, OPRK1 CA12 3553/4885CA1 3927/4885CA2 4481/4885
US-10307416-B2 Oligomer-opioid agonist conjugates OPRM1, OPRL1, OPRK1 CA12 3553/4885CA1 3927/4885CA2 4481/4885
US-20190046523-A1 OLIGOMER-OPIOID AGONIST CONJUGATES OPRM1, OPRL1, OPRK1 CA12 3553/4885CA1 3927/4885CA2 4481/4885
US-20190247388-A1 OLIGOMER-OPIOID AGONIST CONJUGATES OPRM1, OPRL1, OPRK1 CA12 3553/4885CA1 3927/4885CA2 4481/4885
US-20180296550-A1 Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound OPRL1, OPRM1, OPRK1 CA12 3654/4885CA1 3572/4885CA2 1893/4885
US-20120184581-A1 Oligomer-Opioid Agonist Conjugates OPRM1, OPRL1, OPRK1 CA12 3553/4885CA1 3927/4885CA2 4481/4885
US-20100048602-A1 Oligomer-Opioid Agonist Conjugates OPRM1, OPRL1, OPRK1 CA12 3553/4885CA1 3927/4885CA2 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.